Home Pharmaceuticals Natural Killer (NK) Cell Therapeutics Market Size, Growth & Statistics - 2031

Natural Killer (NK) Cell Therapeutics Market Size & Outlook, 2023-2031

Natural Killer (NK) Cell Therapeutics Market Size, Share & Trends Analysis Report By Natural Killer (NK) cell Therapy Type (NK Cell Therapy (unmodified), CAR-NK Cell Therapy (modified), NK Cell Engager), By Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), Bispecific Antibodies), By Application (Cancer, Immunoproliferative Disorders, Acute Infectious Diseases, Gastrointestinal Diseases, Others), By Indication (Hepatocellular Carcinoma (HCC), Acute Myeloid Leukemia (AML), Relapsed Or Refractory (r/r) B-Cell Non-Hodgkin's Lymphoma (NHL), Peripheral T-Cell Lymphoma (PTCL).), By Pipeline Product (AFM13, MG4101, GTA002 (oNKordA), TAK-007) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Report Code: SRPH54334DR
Last Updated : May, 2023
Pages : 110
Author : Mitiksha Koul
Format : PDF, Excel

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Natural Killer (NK) Cell Therapeutics Market Introduction
    2. By Natural Killer (NK) cell Therapy Type
      1. Introduction
        1. Natural Killer (NK) cell Therapy Type By Value
      2. NK Cell Therapy (unmodified)
        1. By Value
      3. CAR-NK Cell Therapy (modified)
        1. By Value
      4. NK Cell Engager
        1. By Value
    3. By Approaches
      1. Introduction
        1. Approaches By Value
      2. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
        1. By Value
      3. Bispecific Antibodies
        1. By Value
    4. By Application
      1. Introduction
        1. Application By Value
      2. Cancer
        1. By Value
      3. Immunoproliferative Disorders
        1. By Value
      4. Acute Infectious Diseases
        1. By Value
      5. Gastrointestinal Diseases
        1. By Value
      6. Others
        1. By Value
    5. By Indication
      1. Introduction
        1. Indication By Value
      2. Hepatocellular Carcinoma (HCC)
        1. By Value
      3. Acute Myeloid Leukemia (AML)
        1. By Value
      4. Relapsed Or Refractory (r/r) B-Cell Non-Hodgkin's Lymphoma (NHL)
        1. By Value
      5. Peripheral T-Cell Lymphoma (PTCL).
        1. By Value
    6. By Pipeline Product
      1. Introduction
        1. Pipeline Product By Value
      2. AFM13
        1. By Value
      3. MG4101
        1. By Value
      4. GTA002 (oNKordA)
        1. By Value
      5. TAK-007
        1. By Value
    1. Introduction
    2. By Natural Killer (NK) cell Therapy Type
      1. Introduction
        1. Natural Killer (NK) cell Therapy Type By Value
      2. NK Cell Therapy (unmodified)
        1. By Value
      3. CAR-NK Cell Therapy (modified)
        1. By Value
      4. NK Cell Engager
        1. By Value
    3. By Approaches
      1. Introduction
        1. Approaches By Value
      2. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
        1. By Value
      3. Bispecific Antibodies
        1. By Value
    4. By Application
      1. Introduction
        1. Application By Value
      2. Cancer
        1. By Value
      3. Immunoproliferative Disorders
        1. By Value
      4. Acute Infectious Diseases
        1. By Value
      5. Gastrointestinal Diseases
        1. By Value
      6. Others
        1. By Value
    5. By Indication
      1. Introduction
        1. Indication By Value
      2. Hepatocellular Carcinoma (HCC)
        1. By Value
      3. Acute Myeloid Leukemia (AML)
        1. By Value
      4. Relapsed Or Refractory (r/r) B-Cell Non-Hodgkin's Lymphoma (NHL)
        1. By Value
      5. Peripheral T-Cell Lymphoma (PTCL).
        1. By Value
    6. By Pipeline Product
      1. Introduction
        1. Pipeline Product By Value
      2. AFM13
        1. By Value
      3. MG4101
        1. By Value
      4. GTA002 (oNKordA)
        1. By Value
      5. TAK-007
        1. By Value
    7. U.S.
      1. By Natural Killer (NK) cell Therapy Type
        1. Introduction
          1. Natural Killer (NK) cell Therapy Type By Value
        2. NK Cell Therapy (unmodified)
          1. By Value
        3. CAR-NK Cell Therapy (modified)
          1. By Value
        4. NK Cell Engager
          1. By Value
      2. By Approaches
        1. Introduction
          1. Approaches By Value
        2. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
          1. By Value
        3. Bispecific Antibodies
          1. By Value
      3. By Application
        1. Introduction
          1. Application By Value
        2. Cancer
          1. By Value
        3. Immunoproliferative Disorders
          1. By Value
        4. Acute Infectious Diseases
          1. By Value
        5. Gastrointestinal Diseases
          1. By Value
        6. Others
          1. By Value
      4. By Indication
        1. Introduction
          1. Indication By Value
        2. Hepatocellular Carcinoma (HCC)
          1. By Value
        3. Acute Myeloid Leukemia (AML)
          1. By Value
        4. Relapsed Or Refractory (r/r) B-Cell Non-Hodgkin's Lymphoma (NHL)
          1. By Value
        5. Peripheral T-Cell Lymphoma (PTCL).
          1. By Value
      5. By Pipeline Product
        1. Introduction
          1. Pipeline Product By Value
        2. AFM13
          1. By Value
        3. MG4101
          1. By Value
        4. GTA002 (oNKordA)
          1. By Value
        5. TAK-007
          1. By Value
    8. Canada
    1. Introduction
    2. By Natural Killer (NK) cell Therapy Type
      1. Introduction
        1. Natural Killer (NK) cell Therapy Type By Value
      2. NK Cell Therapy (unmodified)
        1. By Value
      3. CAR-NK Cell Therapy (modified)
        1. By Value
      4. NK Cell Engager
        1. By Value
    3. By Approaches
      1. Introduction
        1. Approaches By Value
      2. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
        1. By Value
      3. Bispecific Antibodies
        1. By Value
    4. By Application
      1. Introduction
        1. Application By Value
      2. Cancer
        1. By Value
      3. Immunoproliferative Disorders
        1. By Value
      4. Acute Infectious Diseases
        1. By Value
      5. Gastrointestinal Diseases
        1. By Value
      6. Others
        1. By Value
    5. By Indication
      1. Introduction
        1. Indication By Value
      2. Hepatocellular Carcinoma (HCC)
        1. By Value
      3. Acute Myeloid Leukemia (AML)
        1. By Value
      4. Relapsed Or Refractory (r/r) B-Cell Non-Hodgkin's Lymphoma (NHL)
        1. By Value
      5. Peripheral T-Cell Lymphoma (PTCL).
        1. By Value
    6. By Pipeline Product
      1. Introduction
        1. Pipeline Product By Value
      2. AFM13
        1. By Value
      3. MG4101
        1. By Value
      4. GTA002 (oNKordA)
        1. By Value
      5. TAK-007
        1. By Value
    7. U.K.
      1. By Natural Killer (NK) cell Therapy Type
        1. Introduction
          1. Natural Killer (NK) cell Therapy Type By Value
        2. NK Cell Therapy (unmodified)
          1. By Value
        3. CAR-NK Cell Therapy (modified)
          1. By Value
        4. NK Cell Engager
          1. By Value
      2. By Approaches
        1. Introduction
          1. Approaches By Value
        2. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
          1. By Value
        3. Bispecific Antibodies
          1. By Value
      3. By Application
        1. Introduction
          1. Application By Value
        2. Cancer
          1. By Value
        3. Immunoproliferative Disorders
          1. By Value
        4. Acute Infectious Diseases
          1. By Value
        5. Gastrointestinal Diseases
          1. By Value
        6. Others
          1. By Value
      4. By Indication
        1. Introduction
          1. Indication By Value
        2. Hepatocellular Carcinoma (HCC)
          1. By Value
        3. Acute Myeloid Leukemia (AML)
          1. By Value
        4. Relapsed Or Refractory (r/r) B-Cell Non-Hodgkin's Lymphoma (NHL)
          1. By Value
        5. Peripheral T-Cell Lymphoma (PTCL).
          1. By Value
      5. By Pipeline Product
        1. Introduction
          1. Pipeline Product By Value
        2. AFM13
          1. By Value
        3. MG4101
          1. By Value
        4. GTA002 (oNKordA)
          1. By Value
        5. TAK-007
          1. By Value
    8. Germany
    9. France
    10. Spain
    11. Italy
    12. Russia
    13. Nordic
    14. Benelux
    15. Rest of Europe
    1. Introduction
    2. By Natural Killer (NK) cell Therapy Type
      1. Introduction
        1. Natural Killer (NK) cell Therapy Type By Value
      2. NK Cell Therapy (unmodified)
        1. By Value
      3. CAR-NK Cell Therapy (modified)
        1. By Value
      4. NK Cell Engager
        1. By Value
    3. By Approaches
      1. Introduction
        1. Approaches By Value
      2. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
        1. By Value
      3. Bispecific Antibodies
        1. By Value
    4. By Application
      1. Introduction
        1. Application By Value
      2. Cancer
        1. By Value
      3. Immunoproliferative Disorders
        1. By Value
      4. Acute Infectious Diseases
        1. By Value
      5. Gastrointestinal Diseases
        1. By Value
      6. Others
        1. By Value
    5. By Indication
      1. Introduction
        1. Indication By Value
      2. Hepatocellular Carcinoma (HCC)
        1. By Value
      3. Acute Myeloid Leukemia (AML)
        1. By Value
      4. Relapsed Or Refractory (r/r) B-Cell Non-Hodgkin's Lymphoma (NHL)
        1. By Value
      5. Peripheral T-Cell Lymphoma (PTCL).
        1. By Value
    6. By Pipeline Product
      1. Introduction
        1. Pipeline Product By Value
      2. AFM13
        1. By Value
      3. MG4101
        1. By Value
      4. GTA002 (oNKordA)
        1. By Value
      5. TAK-007
        1. By Value
    7. China
      1. By Natural Killer (NK) cell Therapy Type
        1. Introduction
          1. Natural Killer (NK) cell Therapy Type By Value
        2. NK Cell Therapy (unmodified)
          1. By Value
        3. CAR-NK Cell Therapy (modified)
          1. By Value
        4. NK Cell Engager
          1. By Value
      2. By Approaches
        1. Introduction
          1. Approaches By Value
        2. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
          1. By Value
        3. Bispecific Antibodies
          1. By Value
      3. By Application
        1. Introduction
          1. Application By Value
        2. Cancer
          1. By Value
        3. Immunoproliferative Disorders
          1. By Value
        4. Acute Infectious Diseases
          1. By Value
        5. Gastrointestinal Diseases
          1. By Value
        6. Others
          1. By Value
      4. By Indication
        1. Introduction
          1. Indication By Value
        2. Hepatocellular Carcinoma (HCC)
          1. By Value
        3. Acute Myeloid Leukemia (AML)
          1. By Value
        4. Relapsed Or Refractory (r/r) B-Cell Non-Hodgkin's Lymphoma (NHL)
          1. By Value
        5. Peripheral T-Cell Lymphoma (PTCL).
          1. By Value
      5. By Pipeline Product
        1. Introduction
          1. Pipeline Product By Value
        2. AFM13
          1. By Value
        3. MG4101
          1. By Value
        4. GTA002 (oNKordA)
          1. By Value
        5. TAK-007
          1. By Value
    8. Korea
    9. Japan
    10. India
    11. Australia
    12. Taiwan
    13. South East Asia
    14. Rest of Asia-Pacific
    1. Introduction
    2. By Natural Killer (NK) cell Therapy Type
      1. Introduction
        1. Natural Killer (NK) cell Therapy Type By Value
      2. NK Cell Therapy (unmodified)
        1. By Value
      3. CAR-NK Cell Therapy (modified)
        1. By Value
      4. NK Cell Engager
        1. By Value
    3. By Approaches
      1. Introduction
        1. Approaches By Value
      2. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
        1. By Value
      3. Bispecific Antibodies
        1. By Value
    4. By Application
      1. Introduction
        1. Application By Value
      2. Cancer
        1. By Value
      3. Immunoproliferative Disorders
        1. By Value
      4. Acute Infectious Diseases
        1. By Value
      5. Gastrointestinal Diseases
        1. By Value
      6. Others
        1. By Value
    5. By Indication
      1. Introduction
        1. Indication By Value
      2. Hepatocellular Carcinoma (HCC)
        1. By Value
      3. Acute Myeloid Leukemia (AML)
        1. By Value
      4. Relapsed Or Refractory (r/r) B-Cell Non-Hodgkin's Lymphoma (NHL)
        1. By Value
      5. Peripheral T-Cell Lymphoma (PTCL).
        1. By Value
    6. By Pipeline Product
      1. Introduction
        1. Pipeline Product By Value
      2. AFM13
        1. By Value
      3. MG4101
        1. By Value
      4. GTA002 (oNKordA)
        1. By Value
      5. TAK-007
        1. By Value
    7. UAE
      1. By Natural Killer (NK) cell Therapy Type
        1. Introduction
          1. Natural Killer (NK) cell Therapy Type By Value
        2. NK Cell Therapy (unmodified)
          1. By Value
        3. CAR-NK Cell Therapy (modified)
          1. By Value
        4. NK Cell Engager
          1. By Value
      2. By Approaches
        1. Introduction
          1. Approaches By Value
        2. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
          1. By Value
        3. Bispecific Antibodies
          1. By Value
      3. By Application
        1. Introduction
          1. Application By Value
        2. Cancer
          1. By Value
        3. Immunoproliferative Disorders
          1. By Value
        4. Acute Infectious Diseases
          1. By Value
        5. Gastrointestinal Diseases
          1. By Value
        6. Others
          1. By Value
      4. By Indication
        1. Introduction
          1. Indication By Value
        2. Hepatocellular Carcinoma (HCC)
          1. By Value
        3. Acute Myeloid Leukemia (AML)
          1. By Value
        4. Relapsed Or Refractory (r/r) B-Cell Non-Hodgkin's Lymphoma (NHL)
          1. By Value
        5. Peripheral T-Cell Lymphoma (PTCL).
          1. By Value
      5. By Pipeline Product
        1. Introduction
          1. Pipeline Product By Value
        2. AFM13
          1. By Value
        3. MG4101
          1. By Value
        4. GTA002 (oNKordA)
          1. By Value
        5. TAK-007
          1. By Value
    8. Turkey
    9. Saudi Arabia
    10. South Africa
    11. Egypt
    12. Nigeria
    13. Rest of MEA
    1. Introduction
    2. By Natural Killer (NK) cell Therapy Type
      1. Introduction
        1. Natural Killer (NK) cell Therapy Type By Value
      2. NK Cell Therapy (unmodified)
        1. By Value
      3. CAR-NK Cell Therapy (modified)
        1. By Value
      4. NK Cell Engager
        1. By Value
    3. By Approaches
      1. Introduction
        1. Approaches By Value
      2. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
        1. By Value
      3. Bispecific Antibodies
        1. By Value
    4. By Application
      1. Introduction
        1. Application By Value
      2. Cancer
        1. By Value
      3. Immunoproliferative Disorders
        1. By Value
      4. Acute Infectious Diseases
        1. By Value
      5. Gastrointestinal Diseases
        1. By Value
      6. Others
        1. By Value
    5. By Indication
      1. Introduction
        1. Indication By Value
      2. Hepatocellular Carcinoma (HCC)
        1. By Value
      3. Acute Myeloid Leukemia (AML)
        1. By Value
      4. Relapsed Or Refractory (r/r) B-Cell Non-Hodgkin's Lymphoma (NHL)
        1. By Value
      5. Peripheral T-Cell Lymphoma (PTCL).
        1. By Value
    6. By Pipeline Product
      1. Introduction
        1. Pipeline Product By Value
      2. AFM13
        1. By Value
      3. MG4101
        1. By Value
      4. GTA002 (oNKordA)
        1. By Value
      5. TAK-007
        1. By Value
    7. Brazil
      1. By Natural Killer (NK) cell Therapy Type
        1. Introduction
          1. Natural Killer (NK) cell Therapy Type By Value
        2. NK Cell Therapy (unmodified)
          1. By Value
        3. CAR-NK Cell Therapy (modified)
          1. By Value
        4. NK Cell Engager
          1. By Value
      2. By Approaches
        1. Introduction
          1. Approaches By Value
        2. Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
          1. By Value
        3. Bispecific Antibodies
          1. By Value
      3. By Application
        1. Introduction
          1. Application By Value
        2. Cancer
          1. By Value
        3. Immunoproliferative Disorders
          1. By Value
        4. Acute Infectious Diseases
          1. By Value
        5. Gastrointestinal Diseases
          1. By Value
        6. Others
          1. By Value
      4. By Indication
        1. Introduction
          1. Indication By Value
        2. Hepatocellular Carcinoma (HCC)
          1. By Value
        3. Acute Myeloid Leukemia (AML)
          1. By Value
        4. Relapsed Or Refractory (r/r) B-Cell Non-Hodgkin's Lymphoma (NHL)
          1. By Value
        5. Peripheral T-Cell Lymphoma (PTCL).
          1. By Value
      5. By Pipeline Product
        1. Introduction
          1. Pipeline Product By Value
        2. AFM13
          1. By Value
        3. MG4101
          1. By Value
        4. GTA002 (oNKordA)
          1. By Value
        5. TAK-007
          1. By Value
    8. Mexico
    9. Argentina
    10. Chile
    11. Colombia
    12. Rest of LATAM
    1. Natural Killer (NK) Cell Therapeutics Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. GC Cell (GC Biopharma corp.)
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. ImmunityBio Inc.
    3. Nkarta Inc.
    4. Takeda Pharmaceutical Company Limited
    5. Sanofi S. A.
    6. Innate Pharma SA
    7. Glycostem Therapeutics B. V.
    8. Fate Therapeutics Inc.
    9. Dragonfly Therapeutics Inc.
    10. Cytovac A/ S.
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Available for purchase with detailed segment data, forecasts, and regional insights.

Get This Report

Download Free Sample

Note: Please ensure you provide an active email address as we will be sending sample details via email.
The button will be active once the above form is filled

Our Clients:

LG Electronics
AMCAD Engineering
KOBE STEEL LTD.
Hindustan National Glass & Industries Limited
Voith Group
International Paper
Hansol Paper
Whirlpool Corporation
Sony
Samsung Electronics
Qualcomm
Google
Fiserv
Veto-Pharma
Nippon Becton Dickinson
Merck
Argon Medical Devices
Abbott
Ajinomoto
Denon
Doosan
Meiji Seika Kaisha Ltd
LG Chemicals
LCY chemical group
Bayer
Airrane
BASF
Toyota Industries
Nissan Motors
Neenah
Mitsubishi
Hyundai Motor Company

We are featured on :

Address:
Office 515 A, Amanora Chambers,
Amanora Park Town, Hadapsar,
Pune 411028, Maharashtra, India.
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
DMCA.com Protection Status
Secure Payments:
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.